Articles with the keyword: 
Novo Nordisk Seeks U.S. and European Approval for Type 2 Drug Liraglutide
kavin submitted, created time 5 months 2 days (www.diabeteshealth.com)
Drug manufacturer Novo Nordisk has applied to the U.S. Federal Drug Administration and the European Medicines Agency for approval of liraglutide, a human GLP-1 analog that is taken once daily for the treatment of type 2 diabetes.
The company’s applications are based on a study of 6,500 type 2s, 4,200 of whom received liraglutide as a diet and exercise adjunct. Some of the drug’s recipients used it in combination with other medications used to treat diabetes, while others received it as a monotherapy 
athena submitted, created time 1 year 6 months (www.nature.com)
"Insulin-like growth factor-I (IGF-I) and its receptor (IGF-IR) have been implicated in the pathophysiology of many human cancers, including those of hematopoietic lineage. We investigated the therapeutic potential of the novel IGF-IR tyrosine kinase activity inhibitor, NVP-AEW541, on human acute myeloid leukemia (AML) cells. NVP-AEW541 was tested on a HL60 cell subclone, which is dependent on autocrine secretion of IGF-I for survival and drug resistance, as well as primary drug resistant leukemia cells."
\ 1
\ 
abuse@discover8.com
angelfish
Darkfrog
sea-maid
Sue Wu
jane2007
DanyC
addict
siRNA Vector : pRNAT-CMV3.1/Neo
www.genscript.com
Calcitonin, eel
Calcitonin is hypocalcemic hormone produced by the parafolli ...
www.genscript.com
Kyotorphin
Kyotorphin (Kyo), an endogenous neuropeptide (tyrosine-argin ...
www.genscript.com
Granulocyte Colony Stimulating Factor, CHO
Recombinant Human Granulocyte Colony Stimulating Factor is a ...
www.genscript.com